Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28307737 | 0.70 | TRPA1 (0.40) | EPHX1 | |
| SCHEMBL28416887 | 0.69 | EPHX1 (0.32) | EPHX1 | |
| SCHEMBL331898 | 0.69 | EPHX1 (0.32) | EPHX1 | |
| SCHEMBL11423553 | 0.67 | TRPA1 (0.42) | — | |
| SCHEMBL20072332 | 0.65 | EPHX1 (0.39) | EPHX1 | |
| SCHEMBL2589254 | 0.63 | EPHX1 (0.43) | EPHX1 | |
| SCHEMBL4073560 | 0.63 | CA1 (0.37) | EPHX1 | |
| SCHEMBL2768891 | 0.60 | ALDH1A1 (0.42) | EPHX1 | |
| SCHEMBL939785 | 0.60 | ALDH1A1 (0.42) | EPHX1 | |
| SCHEMBL8391552 | 0.60 | EPHX1 (0.34) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150362491-A1 | METHODS AND ASSAYS RELATING TO RNF216 | THE GENERAL HOSPITAL CORPORATION (US) | 2015-12-17 | — | — | US | claimed |
| EP-4387604-A1 | MIXTURES AND COMPOSITIONS COMPRISING SULFORAPHANE AND GLYCINE | Société des Produits Nestlé S.A. (CH) | 2024-06-26 | — | — | EP | disclosed |
| CN-117979963-A | Mixtures and compositions comprising sulforaphane and glycine | 雀巢产品有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023021040-A1 | MIXTURES AND COMPOSITIONS COMPRISING SULFORAPHANE AND GLYCINE | Société des Produits Nestlé S.A. (CH) | 2023-02-23 | — | — | WO | disclosed |
| WO-2016054475-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20150362491-A1 | METHODS AND ASSAYS RELATING TO RNF216 | THE GENERAL HOSPITAL CORPORATION (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2782583-A2 | METHODS AND COMPOSITIONS FOR REDUCING ALCOHOL TOXICITY | The John Hopkins University (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2773212-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF AUTISM | The Johns Hopkins University (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2014110549-A1 | METHODS AND ASSAYS RELATING TO RNF216 | THE GENERAL HOSPITAL CORPORATION (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2013078371-A2 | METHODS AND COMPOSITIONS FOR REDUCING ALCOHOL TOXICITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013067040-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF AUTISM | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20110082099-A1 | Methods and Compositions for the Treatment of Cystic Fibrosis and Related Illnesses | CHILDERS MELANIE | 2011-04-07 | — | — | US | disclosed |
| EP-2205237-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | Johns Hopkins University (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009051739-A1 | METHODS FOR PROTECTING THE SKIN FROM RADIATION INSULTS | JOHNS HOPKINS UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20060258599-A1 | Methods and composition for the treatment of cystic fibrosis and related illnesses | CHILDERS MELANIE | 2006-11-16 | — | — | US | disclosed |
| WO-2002002190-A2 | PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES BY GLUTATHIONE AND PHASE II DETOXIFICATION ENZYMES | JOHNS HOPKINS SCHOOL OF MEDICINE (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150362491-A1 | METHODS AND ASSAYS RELATING TO RNF216 | RNF213, RNF168, STUB1 | EPHX1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.